If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
Knowbe4, Inc. (KNBE)
Zymergen Inc. (ZY)
Neuropace Inc (NPCE)
Upcoming IPO
Agiliti, Inc (AGTI)
Treace Medical Concepts, Inc. (TMCI)
Latham Group, Inc. (SWIM)
Rain Therapeutics Inc. (RAIN)
Impel Neuropharma, Inc. (IMPL)
Ftc Solar, Inc. (FTCI)
Aveanna Healthcare Holdings Inc. (AVAH)
Endeavor Group Holdings (EDR)
The Fortegra Group, Inc. (FRF)
Privia Health Group, Inc. (PRVA)
Priced IPO
Uipath Inc (PATH)
Doubleverify Holdings, Inc. (DV)
Skywater Technology, Inc. (SKYT)
Infobird (IFBD)
Troika Media Group, Inc. (TRKA)
Biomea Fusion, Inc. (BMEA)
Akoya Biosciences, Inc. (AKYA)
Recursion Pharmaceuticals, Inc. (RXRX)
Karat Packaging Inc. (KRT)
AppLovin (APP)
Esports Technologies (EBET)
Agilon Health, Inc. (AGL)
TuSimple Holdings Inc (TSP)
Coinbase Global, Inc. (COIN)
Alkami Technology, Inc. (ALKT)
Reneo Pharmaceuticals, Inc. (RPHM)
Vectivbio Holding Ag (VECT)
UTime Limited (UTME)
Frontier Group Holdings (ULCC)
Compass, Inc. (COMP)
More companies

Vectivbio Holding Ag (VECT)

Sector - Healthcare

Price chart

Return from IPO

Company News

IPO Profile

About company

They are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need. They are led by an experienced management team with a strong track record in the biotechnology and pharmaceutical industry. Their goal is to become a leading, patient-centric, fully integrated global rare disease company. Their current product pipeline is focused on rare gastrointestinal, or GI, disorders, and they intend to in-license or acquire additional transformational, differentiated rare disease assets. Their product candidate, apraglutide, is a next generation, long-acting synthetic peptide analog of glucagon-like peptide-2, or GLP-2, which they are developing as a differentiated therapeutic for a range of rare GI diseases, with an initial focus on short bowel syndrome, or SBS. Based on their preclinical and clinical data to date, they believe that apraglutide has the potential to advance the treatment of SBS intestinal failure, or SBS-IF, by establishing less frequent dosing and improve clinical outcomes. Apraglutide is currently being evaluated in a global Phase 3 clinical trial for the treatment of patients with SBS-IF. They also plan to evaluate apraglutide’s therapeutic potential in additional rare GI conditions, such as graft versus host disease, that could benefit from GLP-2 activation.
Pharmaceutical Preparations
Luca Santarelli Claudia D’Augusta
Employees Founded
25 2019


Address: Aeschenvorstadt 36 4051 Basel Switzerland

Telephone: +41 61 551 30 30

Web page:

IPO information

First Trade Date 4/9/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range $16.00-$18.00
Share prices ($)

Shares & Volumes

Shares Initial (MM) 7.5
Shares Revised (MM) 7.5
Expected offer amount (MM) $127.5
Realized offer amount(MM) $127.5

Financial Data (last reporting year)

Market Cap (MM) $578.17
Revenues (MM) $0
Net Income (Loss) (MM) $-59.94


What do you think will happen with the VECT share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: BofA Securities

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
BofA Securities/ SVB Leerink/ Credit Suisse
LifeSci Capital

Sector: Healthcare

Tweets about $VECT

Tweets volume:

RT volume:


Google Trends Stats